Cargando…
The great wall of inflammatory bowel disease
Autores principales: | Al Sulais, Eman, Raine, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212111/ https://www.ncbi.nlm.nih.gov/pubmed/35418001 http://dx.doi.org/10.4103/sjg.sjg_102_22 |
Ejemplares similares
-
Methotrexate in inflammatory bowel disease: A primer for gastroenterologists
por: AlAmeel, Turki, et al.
Publicado: (2022) -
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020) -
Undisclosed payments by pharmaceutical manufacturers to authors of inflammatory bowel disease guidelines in the United States
por: Al Sulais, Eman, et al.
Publicado: (2021) -
Diagnostic delay of pediatric inflammatory bowel disease in Saudi Arabia—the community, the physicians, and the disease: Where's the hold-up?
por: Sardi, Mais Al, et al.
Publicado: (2019) -
Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study
por: AlAskar, Dimah, et al.
Publicado: (2020)